Literature DB >> 11136278

Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.

F N Hussain1, R A Ajjan, K Kapur, M Moustafa, S A Riley.   

Abstract

BACKGROUND: Delayed-release mesalazine is traditionally taken as three divided doses. However, it is well-recognized that dosing frequency has a significant impact on compliance and that once daily dosing is preferable.
METHODS: We measured serum, urinary, faecal and rectal tissue concentrations of 5-aminosalicylic acid and N-acetyl 5-aminosalicylic acid in 24 healthy volunteers following dosing with delayed-release mesalazine, 1.2 g or 2.4 g daily, given as either a single daily dose at 08:00 hours or in three divided doses at 08:00, 13:00 and 18:00 hours.
RESULTS: Urinary and faecal excretion and rectal tissue concentrations of 5-aminosalicylic acid and N-acetyl 5-aminosalicylic acid were similar following single or divided daily dosing, at both doses studied. Peak serum concentrations were found at 06:00-09:00 following divided dosing and at 17:00-20:00 following once daily dosing. However, peak and trough serum levels and serum area under curve values (AUC) were similar with both regimens and at both doses.
CONCLUSIONS: Urinary, faecal and rectal tissue concentrations are similar following single or divided daily dosing. Minor differences in serum levels were apparent but maximum, minimum and AUC values were similar. Clinical trials should examine the efficacy and toxicity of once daily dosing in patients with ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11136278     DOI: 10.1046/j.1365-2036.2001.00891.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  10 in total

1.  Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease.

Authors:  Javier P Gisbert; María Chaparro; Fernando Gomollón
Journal:  World J Gastroenterol       Date:  2011-08-14       Impact factor: 5.742

2.  Further Validation of the Crohn's and Ulcerative Colitis Questionnaire-32 (CUCQ-32) to Measure the Quality of Life in Patients Treated with Biologics Therapy.

Authors:  Laith Alrubaiy; Rafid Sikafi; Hayley Anne Hutchings; Ian Arnott; John Gordon Williams
Journal:  Clin Pract       Date:  2022-06-10

Review 3.  Evolving medical therapies for ulcerative colitis.

Authors:  Russell D Cohen
Journal:  Curr Gastroenterol Rep       Date:  2002-12

4.  Acute murine colitis reduces colonic 5-aminosalicylic acid metabolism by regulation of N-acetyltransferase-2.

Authors:  Verónica Ramírez-Alcántara; Marshall H Montrose
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-04-17       Impact factor: 4.052

5.  Urinalysis of MMX-mesalazine as a tool to monitor 5-ASA adherence in daily IBD practice.

Authors:  Tessa E H Römkens; Rene Te Morsche; Wilbert Peters; David M Burger; Frank Hoentjen; Joost P H Drenth
Journal:  Br J Clin Pharmacol       Date:  2017-12-06       Impact factor: 4.335

6.  One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis.

Authors:  A Barney Hawthorne; Rachel Stenson; David Gillespie; Edwin T Swarbrick; Anjan Dhar; Kapil C Kapur; Kerry Hood; Chris S J Probert
Journal:  Inflamm Bowel Dis       Date:  2011-11-13       Impact factor: 5.325

7.  Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine.

Authors:  Daniel B Zandman; Mark A Peppercorn
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

8.  Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine.

Authors:  Kavinderjit Nanda; Alan C Moss
Journal:  Clin Pharmacol       Date:  2012-07-25

Review 9.  Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis.

Authors:  Stephan Karl Böhm; Wolfgang Kruis
Journal:  Clin Exp Gastroenterol       Date:  2014-09-23

10.  Similar pharmacokinetics of three dosing regimens comprising two oral delayed-release mesalamine formulations in healthy adult volunteers: Randomised, open-label, parallel-group study.

Authors:  Niels Vande Casteele; Abhijeet Jakate; Brian McNamee; William J Sandborn
Journal:  Br J Clin Pharmacol       Date:  2020-08-10       Impact factor: 3.716

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.